Goldman Sachs is telling investors to take a breath. Peter Oppenheimer, the bank’s chief global equity strategist, has told investors today that markets aren’t crashing—just cooling. “In our view, ...
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
We recently compiled a list of the Top 10 AI Stocks Dominating Wall Street. In this article, we are going to take a look at ...
Hosted on MSN9d
Goldman Sachs recommends investing in these two sectors as the global population agesIts shares were listed on the Nasdaq for the public to trade in 2024. Brightspring stock has more than doubled over the ...
Hedge funds were already waiting to see if a U.S.-fostered, home-grown artificial intelligence boom would continue as China's ...
NCPRR and NLPC sent Goldman and JPMorgan the anti-DEI proposals, while Bank of America and Citi received proposals from NLPC ...
Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment bank ...
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback